IQVIA announced a strategic collaboration with SCRI Development Innovations, the contract research organization arm of Sarah Cannon Research Institute, to transform oncology trials globally. This partnership aims to enhance clinical trial processes and expedite the availability of new cancer therapies.
The collaboration combines IQVIA’s global reach and expertise in managing oncology trials with SCRI Development Innovations' community oncology expertise and its Accelero operational model. Accelero is designed to expedite trial activation and enhance recruitment for SCRI sites in the United States.
By integrating their capabilities, the companies expect to eliminate operational hurdles and accelerate data delivery, offering sponsors a more effective pathway for developing innovative cancer treatments. This strategic alliance reinforces IQVIA's commitment to advancing medical research in critical disease areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.